文摘
Objectives: The expression pattern of PAX5 in thetissue of superficial bladder transitional cell carcinoma (TCC), itsprognostic value and its correlation with p53immunohistochemistry and p53 mutation analysis were evaluated.Methods: Study comprised 61 patients with histologicallyconfirmed superficial bladder TCC. Expression level of PAX5mRNA was investigated using reverse transcriptase-polymerase chainreaction (RT-PCR) and determined semiquantitatively. The presence ofp53 mutations was determined by SSCP and confirmed by directsequencing. The p53 immunohistochemistry was performed with DO1antibody and semiquantitatively evaluated using HSCORE (HS) method. Asthe control group for the evaluation of the PAX5 expressionserved 8 men with benign prostatic hyperplasia. Results:PAX5 expression was found in 50 patients with bladder TCC butin no patient from the control group. Its quantity however correlatedneither with the stage nor with the grade of the tumor. P53mutation was confirmed only in 1 patient with pTaG2 tumor in exon 5(deletion of proline 128). On the contrary, positive immunohistochemicalstaining of p53 was detected in most patients. Using the cutoffvalue of HS 200, 56.9% of patients showed p53overexpression. Quantity of p53 immunochistochemical positivitydid not correlate with the quantity of PAX5 expression. Usingthe cutoff values of HS 200 for p53 and of 0.2 forPAX5, 7 of 8 patients with future progression had p53and 4 had PAX5 overexpression respectively.Conclusion: The expression of gene PAX5 is a frequentevent in superficial TCC of the bladder.
